ZTS Q3 2026 Revenue Falls 1% to $2.391B; Full-Year EPS Guidance Raised to $6.25–$6.35
· The NYC Memo
Zoetis reported Q3 2026 revenue of $2.391 billion, down 1% year-over-year on both a reported and organic operational basis, with GAAP diluted EPS of $1.44 (-12% YoY) and adjusted diluted EPS of $1.75 (+3% reported). U.S. segment revenue declined 6% to $1.246 billion, driven by weakness in companion animal dermatology and generic competition, while the International segment rose 4% to $1.116 billion.
The company narrowed full-year 2026 revenue guidance to $9.220–$9.320 billion and raised adjusted diluted EPS guidance to $6.25–$6.35 from the prior range of $6.15–$6.25, based on FX rates as of October 20, 2026.